Constellation Energy and Vistra stock surge after PJM capacity auction results
William E. Berry Jr., Vice President and Chief Accounting Officer at Stryker Corp (NYSE:SYK), recently sold shares in the company. On February 2, Berry disposed of 755 shares of common stock at a price of $279.96 per share, totaling approximately $211,369. The stock has since climbed to $376.62, with Stryker maintaining a robust market capitalization of $144 billion. According to InvestingPro analysis, the company currently appears to be trading above its Fair Value, with a "GREAT" overall financial health score. Following this transaction, Berry holds 1,853 shares directly. The filing was amended to correct the number of Restricted Stock Units held by Berry. The stock generally trades with low price volatility and has maintained dividend payments for 35 consecutive years. For deeper insights into insider trading patterns and comprehensive valuation metrics, InvestingPro subscribers can access the detailed Pro Research Report, available for over 1,400 US stocks.
In other recent news, Stryker Corporation reported a strong first-quarter performance with a 10.1% organic revenue growth, exceeding expectations. The company’s total revenues reached approximately $5.9 billion, with significant contributions from the MedSurg and Orthopedics divisions. Despite lowering its earnings per share (EPS) guidance for 2025 due to tariff impacts and the closure of the Neurovascular Associates, Inc. deal, Stryker raised its organic growth forecast to 8.5% to 9.5% for the year. UBS analyst Danielle Antalffy increased the price target for Stryker shares to $421, citing better-than-expected sales and EPS, while maintaining a Neutral rating. Meanwhile, Evercore ISI adjusted its price target to $390, maintaining an Outperform rating, following the company’s robust gross margin performance and operating margin expansion. Stryker also announced an increase in its quarterly dividend to $0.84 per share, demonstrating its commitment to delivering shareholder value. Additionally, the company received FDA 510(k) clearance for its OptaBlate basivertebral nerve ablation system, a new option for chronic back pain relief. Shareholders recently approved amendments to key incentive plans during the Annual Meeting, supporting Stryker’s strategic direction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.